Search results
BioNTech (BNTX) to Report Q1 Earnings: Is a Beat in Store?
Zacks· 5 days agoBioNTech’s top line currently comprises sales of its mRNA-based COVID-19 vaccine, Comirnaty, developed in partnership ...
Smart Money Is Betting Big In MRNA Options - Moderna (NASDAQ:MRNA)
Benzinga· 5 days agoThe firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States ...
Why are nearly half of all recent biotech RNA alliances in Asia-Pacific betting big on...
BioPharma-Reporter· 5 days agoAlmost half of all strategic alliances focused on RNA therapies over the last five years in the...
Why Africa is facing an uphill battle to make its own vaccines
Daily Telegraph· 4 days agoBiotechnology analysts believe that mRNA will become the superior vaccine technology within the next...
Moderna Puts Up Big Quarterly Beat; Could Shares Break Out?
Investor's Business Daily· 3 days agoModerna (MRNA) beat Wall Street's first-quarter expectations Thursday. The Covid vaccine maker came...
Study identifies immunity threshold for protection against COVID-19 in children
Medical Xpress· 5 days agoAll participants received two doses of 10mcg Pfizer/BioNTech mRNA COVID-19 vaccination, 21 days apart. The team followed up with the ...
Moderna Q1 earnings: lower-than-expected loss of $1.18 billion sets tone for vaccine launch | Invezz
Invezz· 3 days agoModerna Inc (NASDAQ: MRNA) reported a narrower-than-expected loss for the first quarter of the year,...
Moderna Reports First Quarter 2024 Financial Results and Provides Business Updates
Digital Journal· 3 days agoReports first quarter revenues of $167 million, GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)Prepares for launches of RSV vaccine and Spikevax® 2024-2025 formula ...
Safe and Effective? The New York Times Revisits the COVID Jab. - The American Spectator | USA News...
American Spectator· 1 day agoIt has taken three years, but the New York Times has finally admitted that maybe, just maybe, there are some serious side effects to COVID vaccines. AstraZeneca, which has ...
Moderna reports $1.2bn net loss in Q1 2024
Pharmaceutical Technology via Yahoo Finance· 2 days agoThe company attributed the decline to the reduced sales of its Covid-19 vaccine. Net product sales plummeted by 91% compared to Q1 2023 ...